Reduce the time needed for vaccine QC, without compromising quality

[Online Version]( [Sartorius] [Sartorius] [pharma-qc-BSC_Outsource_8857-640.png]() 70% of vaccine production time is dedicated to quality control.1 We can safely reduce that. While testing for microbial contamination during the vaccine manufacturing process is essential to ensure quality and patient safety – it’s time-consuming and labor intensive. The latest advances in QC microbiology offer improved sensitivity and specificity, and accelerate workflows, without increasing risk to your process, product or patients. We’ve highlighted some of these advanced quality control strategies for use in viral vector, inactivated and recombinant protein vaccine production in a new article entitled “[Addressing Quality Control Challenges in Vaccine Manufacturing]()”. Download it today and explore the latest technologies for mycoplasma detection, microbial enumeration, sterility testing and air monitoring. Learn how these approaches can accelerate, streamline, and increase the sensitivity and specificity of your vaccine QC workflows. [Download Editorial]() 1 [Contact Us]() [Facebook]() [Twitter]() [YouTube]() [LinkedIn]() About this Newsletter Published by Sartorius AG Otto-Brenner-Straße 20 37079 Goettingen, Germany Phone +49.551.308-0 Fax +49.551.308-3289 [newsletter@sartorius.com]()[www.sartorius.com]() Executive Board Chairman Dr. Joachim Kreuzburg, Rainer Lehmann René Fáber, Gerry Mackay Chairman of the Supervisory Board: Dr. Lothar Kappich Registered Office: Goettingen, Germany Local Court of Registration: Amtsgericht Goettingen, HRB No. 1970 Vat No. DE 115 302 222 Unsubscribe Newsletter If you do not wish to receive any more information from Sartorius, please [click here.]()